Spectrum: Local Antimicrobial Stewardship, for Saskatchewan Health Authority - Saskatoon Area

Fidaxomicin

Restricted
Restricted

C. diff Risk

None

Oral Bioavailability

NA

Spectrum Of Activity

General Spectrum of Activity

Spectrum Of Activity

Dosing

Renal

No dosage adjustment required

Adult

C. difficile
200mg po BID x 10days

Must be approved for usage by Infectious Diseases and Pharmacy to confirm supply

Restricted Use

Must be approved for usage by Infectious Diseases and Pharmacy to confirm supply

General Information

Common Usage

Common Usage

C. difficile colitis refractory to first line therapies and/or re-infection not responding to conventional therapies.

Adverse Effects

Adverse Effects

  •  GI disturbance

  •  Cytopenias

  •  Hypersensitivity: facial, tongue or throat swelling

Additional Information

Additional Information

Consult Infectious Diseases prior to usage

Pharmacology

Pharmacology

Antimicrobial class: Specialized anti-C. difficile macrocyclic agent

Pregnancy category: B

Urine penetration: None

Lung penetration: None

CSF penetration: None

Biliary penetration: None